IAA-94_氯化物通道抑制剂_54197-31-8_Apexbio

合集下载

E-4031_阻断ATP敏感性钾通道的抗心律不齐药物_113558-89-7_Apexbio

信号通路:
Potassium Channel
产品描述:
作用于 hERG 的 IC50 为 7.7 nM。 E-4031 是一种阻断 ATP 敏感性钾通道的抗心律失常药。 ATP 敏感性钾通道广泛分布于包括肌肉、胰腺β细胞和脑在内的组织中。其活性受腺嘌呤核苷酸调节，由 ATP 水平下降和 ADP 水平上升激活。因此，ATP 敏感性钾通道将细胞代谢与膜
特别声明
产品仅用于研究，
不针对患者销售，望谅解。
每个产品具体的储存和使用信息显示在产品说明书中。ApexBio 产品在推荐的条件下是稳定的。产品会根据不同的推荐温度进行运输。许多产品短期运输是稳定的，运输温度不同于长期储存的温度。我们确保我们的产品是在保持试剂质量的条件下运输的。收到产品后，按照产品说明书上的要求进行储存。
产品说明书
化学性质
产品名: Cas No.: 分子量: 分子式:
E-4031 113558-89-7 401.52 C21H27N3O3S
产品名: E-4031 修订日期: 6/30/2016
化学名:
SMILES: 溶解性: 储存条件methylpyridin-2-yl)ethyl)piperidine-4-carbonyl)phenyl) methanesulfonamide
Evaluation sample solution : ship with blue ice All other available size: ship with RT , or blue ice upon request
生物活性
靶点 :
Membrane Transporter/Ion Channel
CC1=NC(CCN2CCC(C(C3=CC=C(NS(C)(=O)=O)C=C3)=O)CC2)=CC=C1

Thioetheramide-PC_竞争性的可逆分泌型磷脂酶A2(sPLA2)抑制剂_116457-99-9_Apexbio

//struct//
1-Palmitylthio-2-palmitoylami do-1,2-dideoxy-sn-glycero-3-p hosphorylcholine
1,2-dideoxy-1-(S-hexadecyl)thio-2-(N-hexadecanoyl)amino-sn-glycer yl-3-phosphorylcholine
ApexBio Technology
Evaluation sample solution : ship with blue ice All other available size: ship with RT , or blue ice upon request
靶点 :
Metabolism
信号通路:
Phospholipase
产品描述:
Thioetheramide-PC is a competitive, reversible inhibitor of secretory phospholipase A2 (sPLA2) [1]. Thioetheramide-PC is a structurally modified phospholipid.
hioetheramide-PC 修订日期: 6/30/2016
产品名: Cas No.: 分子量: 分子式: 别名:
化学名: SMILES: 溶解性: 储存条件: 一般建议:
运输条件:
生物活性
Thioetheramide-PC
116457-99-9
735.1 C40H83N2O5PS
PLA2s hydrolyze the sn-2 ester bond of phospholipids, releasing fatty acids and lysophospholipids, both of which may alter cell function. PLA2s play vital roles in cellular signaling and a wide number of pathophysiological situations, ranging from systemic and acute inflammatory conditions to cancer [2]. sPLA2 promote inflammation in mammals. High levels of sPLA2 contributes to several inflammatory diseases, and has been shown to promote vascular inflammation correlating with coronary events in coronary artery disease and acute coronary syndrome, and possibly leading to acute respiratory distress syndrome and progression of tonsillitis [3]. Thioetheramide-PC inhibited secretory phospholipase A2 (sPLA2) by binding to the catalytic site of sPLA2. The IC50 value was 2 μM [1]. Thioetheramide-PC could also bind to the activator site of this enzyme, which was tighter than its binding to the catalytic site. This dual interaction was that at low concentrations thioetheramide-PC might activate phospholipase activity rather than inhibiting it [1]. 参考文献:

FDA批准的放射性药物都有哪些？

FDA批准的放射性药物都有哪些？展开全文中华医学会核医学分会放射性药物学组整理1、药物名称：Carbon-11 choline（11C-胆碱）生产商：Mayo Clinic 商品名：—用途：前列腺癌复发诊断2、药物名称：Carbon-14 urea（14C-尿素）生产商：Kimberly-Clark 商品名：PYtest用途：胃中幽门螺杆菌感染诊断3、药物名称：Fluorine-18 florbetaben（18F-AV1）生产商：Piramal Imaging 商品名：Neuraceq™用途：阿尔茨海默（AD）患者和痴呆患者评价4、药物名称：Fluorine-18florbetapir（18F-AV45）生产商：Eli Lilly 商品名：Amyvid™用途：阿尔茨海默症诊断与治疗5、药物名称：Fluorine-18sodium fluoride（18F-氟化钠）生产商：Various 商品名：—用途：成骨能力的骨显像剂6、药物名称：Fluorine-18fludeoxyglucose（18F-FDG）生产商：Various 商品名：—用途：肿瘤、癫痫病灶糖代谢异常检测7、药物名称：Fluorine-18flutemetamol（18F-PIB）生产商：GE Healthcare 商品名：Vizamyl用途：阿尔茨海默（AD）患者和痴呆患者评价8、药物名称：Gallium-67 citrate（67Ga-柠檬酸）生产商：Lantheus MedicalImaging、Mallinckrodt商品名：—用途：霍奇金病、淋巴瘤、支气管癌以及一些急性炎症病变诊断9、药物名称：Indium-111capromab pendetide（111In-卡罗单抗喷地肽）生产商：AytuPharmaceuticals 商品名：ProstaScint®用途：前列腺癌患者、前列腺癌术后高度怀疑转移患者的检测10、药物名称：Indium-111 chloride（111In-氯化铟）生产商：GE Healthcare、Mallinckrodt 商品名：Indiclor™用途：用于放射性标记11、药物名称：Indium-111 pentetate（111In-DTPA）生产商：GE Healthcare 商品名：—用途：放射性核素脑池造影12、药物名称：Indium-111oxyquinoline（111In-羟基喹啉）生产商：GE Healthcare 商品名：—用途：用于自体白细胞标记，炎症及感染的诊断13、药物名称：Indium-111pentetreotide（111In-奥曲肽）生产商：Mallinckrodt 商品名：Octreoscan™用途：原发性和转移性内神经分泌肿瘤生长抑素受体定位14、药物名称：Iodine I-123iobenguane（123I-MIBG）生产商：GE Healthcare 商品名：AdreView™用途：原发或转移性嗜铬细胞瘤或神经母细胞瘤的辅助诊断15、药物名称：Iodine I-123 ioflupane（123I-氟潘）生产商：GE Healthcare 商品名：DaTscan™用途：对疑似帕金森症患者的评估16、药物名称：Iodine I-123sodium iodide capsules（123I-碘化钠胶囊）生产商：Cardinal Health、Mallinckrodt 商品名：—用途：甲状腺功能及形态学评价17、药物名称：Iodine I-125 humanserum albumin（125I-人血清白蛋白）生产商：IsoTex Diagnostics 商品名：Jeanatope用途：全血及血浆容量测定18、药物名称：Iodine I-125iothalamate（125I-酞酸盐）生产商：IsoT ex Diagnostics商品名：Glofil-125用途：肾小球滤过率的评价19、药物名称：Iodine I-131 humanserum albumin（131I-人血清白蛋白）生产商：IsoTex Diagnostics 商品名：Megatope用途：全血及血浆量、心脏输出、心脏及肺血容量、蛋白质周转研究、脑肿瘤定位等20、药物名称：Iodine I-131sodium iodide（131I-碘化钠）生产商：DRAXIMAGE、Mallinckrodt 商品名：HICON™用途：甲状腺疾病的诊断与治疗21、药物名称：MolybdenumMo-99 generator（钼锝发生器）生产商：GE Healthcare、Lantheus MedicalImaging、Mallinckrodt商品名：DRYTEC™、T echnelite、UltraTechneKow®DTE用途：放射性药物的制备22、药物名称：Nitrogen-13 ammonia（13N-氨水）生产商：Various 商品名：—用途：心肌灌注评价冠状动脉疾病23、药物名称：Radium-223 dichloride（223Ra-二氯化镭）生产商：Bayer HealthCarePharmaceuticalsInc. 商品名：Xofigo®用途：去势性前列腺癌治疗24、药物名称：Rubidium-82 chloride（82Ru-氯化铷）生产商：Bracco Diagnostics 商品名：Cardiogen-82®用途：心肌灌注显像剂25、药物名称：Samarium-153lexidronam（153Sm-EDTMP）生产商：Lantheus MedicalImaging 商品名：Quadramet®用途：减轻骨转移患者的疼痛26、药物名称：Strontium-89 chloride（89Sr-氯化锶）生产商：GE Healthcare商品名：MetastronTM用途：减轻骨转移患者的疼痛27、药物名称：T echnetium-99mbicisate（99mT c-ECD）生产商：Lantheus MedicalImaging 商品名：Neurolite®用途：脑卒中患者卒中的诊断与治疗28、药物名称：Technetium-99mdisofenin（99mTc-地索芬宁）生产商：Pharmalucence 商品名：Hepatolite®用途：急性胆囊炎诊断29、药物名称：Technetium-99mexametazine（99mTc-HMPAO）生产商：GE Healthcare 商品名：C eretec™用途：脑卒中患者血脑灌注、白细胞标记显像用用于腹腔感染及肠道炎症定位30、药物名称：T echnetium-99mmacroaggregatedalbumin （99mT c-MAA）生产商：DRAXIMAGE 商品名：—用途：肺灌注评价、腹静脉分流畅通性评价31、药物名称：Technetium-99mmebrofenin（99mT c-甲溴苯宁）生产商：Bracco Diagnostics、Pharmalucence 商品名：Choletec®用途：肝胆显像剂32、药物名称：Technetium-99mmedronate（99mTc-MDP）生产商：DRAXIMAGE、GE Healthcare、Pharmalucence 商品名：MDP-25、MDP Multidose用途：骨显像剂33、药物名称：Technetium-99mmertiatide（99mTc-MAG3）生产商：Mallinckrodt 商品名：TechnescanMAG3TM用途：肾动态显像34、药物名称：Technetium-99moxidronate（99mT c-HDP）生产商：Mallinckrodt 商品名：Tec hnescan™HDP用途：骨显像剂35、药物名称：Technetium-99mpentetate（99mT c-DTPA）生产商：DRAXIMAGE 商品名：—用途：脑显像、肾显像36、药物名称：T echnetium-99mpyrophosphate（99mTc-PYP）生产商：Mallinckrodt、Pharmalucence 商品名：Technescan™、PYP™用途：骨显像、心脏显像剂、血池显像剂37、药物名称：Technetium-99m redblood cells（99mT c-红细胞）生产商：Mallinckrodt 商品名：UltraTag™用途：血池造影、消化道出血定位38、药物名称：T echnetium-99msestamibi（99mTc-MIBI）生产商：Cardinal Health、DRAXIMAGE、Lantheus MedicalImaging、Mallinckrodt、Pharmalucence商品名：Cardiolite®用途：心肌灌注，用于检测缺血、评价心机功能，乳腺成像39、药物名称：Technetium-99msodium pertechnetate （99mT c-高锝酸钠）生产商：GE Healthcare、Lantheus MedicalImaging、Mallinckrodt商品名：—用途：脑显像、甲状腺显像、胎盘定位、膀胱显像等40、药物名称：Technetium-99msuccimer（99mT c-DMSA）生产商：GE Healthcare 商品名：—用途：肾显像41、药物名称：Technetium-99msulfur colloid（99mT c-硫胶体）生产商：Pharmalucence 商品名：—用途：肝、脾、骨髓显像等42、药物名称：Technetium-99mtetrofosmin（99mTc-替曲膦）生产商：GE Healthcare 商品名：MyoviewTM用途：心肌灌注剂43、药物名称：Technetium-99mtilmanocept（99mTc-替马诺噻）生产商：NavideaBiopharmaceuticals,Inc. 商品名：Lymphoseek®用途：淋巴结定位44、药物名称：Thallium-201chloride（201Tl-氯化铊）生产商：GE Healthcare、Lantheus MedicalImaging、Mallinckrodt商品名：—用途：心肌灌注显像45、药物名称：Xenon-133 gas（133Xe气体）生产商：Lantheus MedicalImaging 商品名：—用途：肺功能评估与肺显像、脑血流评估46、药物名称：Yttrium-90chloride（90Y-氯化钇）生产商：MDS Nordion、Eckert＆ZieglerNuclitec商品名：—用途：放射性标记47、药物名称：Yttrium-90ibritumomab tiuxetan（90Y-替伊莫单抗）生产商：SpectrumPharmaceuticals商品名：Zevalin®用途：非霍奇金氏淋巴瘤治疗截止至2015年8月1日。

Cyproheptadine hydrochloride_血清素受体拮抗剂_969-33-5_Apexbio

产品说明书
化学性质
产品名: Cas No.: 分子量: 分子式:
产品名: Cyproheptadine hydrochloride 修订日期: 6/30/2016
Cyproheptadine hydrochloride 969-33-5 323.86 C21H22ClN
化学名:
SMILES: 溶解性: 储存条件: 一般建议:
产品描述:
Cyproheptadine hydrochloride 是血清素受体拮抗剂[1]. Cyproheptadine 是血清素和组胺的拮抗剂,同时也是抗毒蕈碱制剂.其用于治疗胃切除术后倾倒综合征\瘙痒性皮肤病\偏头痛\厌食症及垂体依赖性库欣综合征.Cyproheptadine 的主要尿产物是 Cyproheptadine 葡萄糖醛酸—一种季铵化合物.Cyproheptadine 具有一些副作用,包括镇静\嗜睡\低血压\心动过速和血恶液质.作为 5-HT2A 受体的拮抗剂,体外和离体实验中
特别声明
产品仅用于研究，不针对患者销售，望谅解。 ቤተ መጻሕፍቲ ባይዱ个产品具体的储存和使用信息显示在产品说明书中。ApexBio 产品在推荐的条件下是稳定的。产品会根据不同的推荐温度进行运输。许多产品短期运输是稳定的，运输温度不同于长期储存的温度。我们确保我们的产品是在保持试剂质量的条件下运输的。收到产品后，按照产品说明书上的要求进行储存。
For obtaining a higher solubility , please warm the tube at 37°C and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20°C for several months.

Psalmotoxin 1_酸敏感离子通道1a(ASIC1a)阻断剂_Apexbio

特别声明
产品仅用于研究，
不针对患者销售，望谅解。
每个产品具体的储存和使用信息显示在产品说明书中。ApexBio 产品在推荐的条件下是稳定的。产品会根据不同的推荐温度进行运输。许多产品短期运输是稳定的，运输温度不同于长期储存的温度。我们确保我们的产品是在保持试剂质量的条件下运输的。收到产品后，按照产品说明书上的要求进行储存。
ApexBio Technology
产品说明书
化学性质
产品名: Cas No.: 分子量: 分子式:
Psalmotoxin 1
4689.39 C200H312N62O57S6
产品名: Psalmotoxin 1 修订日期: 6/30/2016
化学名: SMILES:
溶解性: 储存条件: 一般建议:
运输条件:
CCC(C(/N=C(O)\C(/N=C(O)/C(/N=C(O)/C(N)CCC(O)=O)CC(O)=O)CSSC C1C(O)=NC(C(O)=NCC(O)=NC(C(O)=NC(C(O)=NC(/C(O)=N/C(/C(O)=N /C(/C(O)=N/C(/C(O)=N/C(/C(O)=N/C(/C(O)=N\C(/C(O)=N/C(/C(O)=N/ C(/C(O)=N/C(/C(O)=N/2)C(C)C)CCC(O)=O)CC3=CC=CC=C3)CO)CCCNC (N)=N)CCCNC(N)=N)CC
Soluble to 2 mg/ml in sterile water
Store at -20°C
For obtaining a higher solubility , please warm the tube at 37°C and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20°C for several months.

GGsTop_γ谷氨酰转肽酶(GGT)抑制剂_926281-37-0_Apexbio

不针对患者销售，望谅解。
每个产品具体的储存和使用信息显示在产品说明书中。ApexBio 产品在推荐的条件下是稳定的。产品会根据不同的推荐温度进行运输。许多产品短期运输是稳定的，运输温度不同于长期储存的温度。我们确保我们的产品是在保持试剂质量的条件下运输的。收到产品后，按照产品说明书上的要求进行储存。
ApexBio Technology
GGsTop 是一种新型的、高选择性的和不可逆的γ谷氨酰转肽酶（GGT）抑制剂，其 Ki 值为 0.17 mM[1]。 GGT 在血浆谷胱甘肽（GSH）和其 S-结合物的代谢过程中起着重要作用，通过水解和/或肽基转移作用来切断γ谷氨酰胺键。GGT 存在于肺中，是一种与表面活性剂磷脂相关的水溶性酶，控制 LLF（肺内衬液）中谷胱甘肽胞外库的平衡。在人类酶中，Cys-Gly 结合位点上的特
Evaluation sample solution : ship with blue ice All other available size: ship with RT , or blue ice upon request
生物活性
靶点 :
Metabolism
信号通路:
Transferase
产品描述:
O=[P@](OC)(CC[C@@H](C(O)=O)N)OC1=CC=CC(CC(O)=O)=C1
Soluble in DMSO > 10 mM
Store at -20°C
For obtaining a higher solubility , please warm the tube at 37°C and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20°C for several months.

PHA-848125_有效的ATP竞争性CDK抑制剂_802539-81-7_Apexbio

实验操作
细胞实验: 细胞系溶解பைடு நூலகம்法
反应时间应用
GL-Mel 细胞
该化合物在 DMSO 中的溶解度大于 23.1 mg/mL。若获取更高浓度的溶液，可在 37℃下孵育 10 分钟，随后在超声波浴中摇匀。-20℃ 以下可储存数月。
在 GL-Mel 细胞中，PHA-848125（0.156 μM）诱导 G1 细胞的适度增加，对 S 和 G2/M 期没有明显影响。PHA-848125（0.625 μ M）处理导致 G1 期细胞显著积累，同时伴随着 S 期和 G2/M 期细胞百分比的强烈降低。PHA-848125 略微上调了 GL-Mel 细胞中 p53 的表达。针对来自不同实体瘤的 145 个肿瘤细胞系和另外 44 个源自白血病和淋巴瘤的细胞系，PHA-848125 显示出抗增殖活性。
ApexBio Technology
Evaluation sample solution : ship with blue ice All other available size: ship with RT , or blue ice upon request
生物活性
靶点 :
Cell Cycle/Checkpoint
信号通路:
Cyclin-Dependent Kinases
特别声明
产品仅用于研究，
不针对患者销售，望谅解。
每个产品具体的储存和使用信息显示在产品说明书中。ApexBio 产品在推荐的条件下是稳定的。产品会根据不同的推荐温度进行运输。许多产品短期运输是稳定的，运输温度不同于长期储存的温度。我们确保我们的产品是在保持试剂质量的条件下运输的。收到产品后，按照产品说明书上的要求进行储存。
参考文献: [1]. Caporali S, Alvino E, Starace G, et al. The cyclin-dependent kinase inhibitor PHA-848125 suppresses the in vitro growth of human melanomas sensitive or resistant to temozolomide, and shows synergistic effects in combination with this triazene compound[J]. Pharmacological research, 2010, 61(5): 437-448. [2]. Albanese C, Alzani R, Amboldi N, et al. Dual targeting of CDK and tropomyosin receptor kinase families by the oral inhibitor PHA-848125, an agent with broad-spectrum antitumor efficacy[J]. Molecular cancer therapeutics, 2010, 9(8): 2243-2254. [3]. Degrassi A, Russo M, Nanni C, et al. Efficacy of PHA-848125, a cyclin-dependent kinase inhibitor, on the K-RasG12DLA2 lung adenocarcinoma transgenic mouse model: evaluation by multimodality imaging[J]. Molecular cancer therapeutics, 2010, 9(3): 673-681.

VPS34-IN1_Vps34抑制剂_1383716-33-3_Apexbio

FYVE 结构域的蛋白质亚型来调节膜转运过程。体外：经鉴定，VPS34-IN1 能够抑制体外 Vps34，但不显著抑制所测试的 340 种蛋白激酶或 25 种脂质激酶的活性，包括 I 型和 II 型 PI3K 的所有同种型。VPS34-IN1 处理细胞剂量依赖性地诱导特异性 PtdIns（3）P 结合探针的快速分散，而不改变 I 型 PI3K 调节 Akt 的能力。此外， VPS34-IN1 也可以在 1 分钟内诱导 SGK3 磷酸化约 50-60％的快速损失。然而，VPS34-IN1 不能抑制无 PtdIns（3）P 结合 PX 结构域的 SGK2 同种型的活性。此外，VPS34-IN1 和 I 型 PI3K 抑制剂 GDC-0941 的联合用药导致 SGK3 活性降低约 80-90％。因此，这些数据表明，VPS34-IN1 是描述 Vps34 生理作用的有用探针，并且 I 型（例如 GDC-0941）和 III 型（如 VPS34-IN1）PI3K 抑制剂的联合用药可用于更好地分析 II PI3K 的作用和调节[1]。体内：迄今为止，尚无动物体内数据报道。临床试验：到目前为止，VPS34-IN1 仍处于临床前研究阶段。
Evaluation sample solution : ship with blue ice All other available size: ship with RT , or blue ice upon request
生物活性
靶点 :
Ubiquitination/ Proteasome
信号通路:
Autophagy
产品描述:
IC50 为 25 nM。 VPS34-IN1 是一种 Vps34 抑制剂。液泡蛋白质分选 34（Vps34）III 型磷酸肌醇 3-激酶（PI3K）磷酸化磷脂酰肌醇（PtdIns）以产生 PtdIns（3）P，PtdIns（3）P 通过募集具有结合 PtdIns（3）P 的 phox 同源域（PX）和

Cathepsin G Inhibitor I_Cathepsin G抑制剂_429676-93-7_Apexbio

产品说明书
化学性质
产品名: Cas No.: 分子量: 分子式:
Cathepsin G Inhibitor I 429676-93-7 620.64 C36H33N2O6P
产品名: Cathepsin G Inhibitor I 修订日期: 6/30/2016
化学名: SMILES: 溶解性: 储存条件: 一般建议:
ApexBio Technology
特别声明
产品仅用于研究，
不针对患者销售，望谅解。
每个产品具体的储存和使用信息显示在产品说明书中。ApexBio 产品在推荐的条件下是稳定的。产品会根据不同的推荐温度进行运输。许多产品短期运输是稳定的，运输温度不同于长期储存的温度。我们确保我们的产品是在保持试剂质量的条件下运输的。收到产品后，按照产品说明书上的要求进行储存。
>10.4mg/mL in DMSO
Store at -20°C
For obtaining a higher solubility , please warm the tube at 37°C and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20°C for several months.
12 nM（n = 10）和 63 ± 14 nM（n = 5）。与其它丝氨酸蛋白酶相比，Cathepsin G Inhibitor I 对 cathepsin G 具有选择性，对糜蛋白酶作用较弱（Ki = 1.5 ± 0.2 μM），对凝血酶、因子 Xa、因子 IXa、纤溶酶、胰蛋白酶、类胰蛋白酶、蛋白酶 3 和人白细胞弹性蛋白酶的抑制作用极弱（在 100μM 时具有<50%的抑制）[1]。体内试验：Cathepsin G Inhibitor I 目前正用于体外研究，没有相关的动物实验[1]。临床试验：Cathepsin G Inhibitor I 目前处于临床前开发阶段，没有相关的临床试验[1]。参考文献: [1] Greco MN, Hawkins MJ, Powell ET, Almond HR Jr, Corcoran TW, de Garavilla L, Kauffman JA, Recacha R, Chattopadhyay D, Andrade-Gordon P, Maryanoff BE. Nonpeptide inhibitors of cathepsin G: optimization of a novel beta-ketophosphonic acid lead by structure-based drug design. J Am Chem Soc. 2002;124(15):3810-1.

放射免疫诊断试剂盒

20-1000 (pg/ml)
非平衡法 24h+24h
50 100
490 700
RP-004
降钙素基因相关肽 (CGRP)
20-1200 (pg/ml)
非平衡法 48h+24h
50 100
490 700
RP-005 RJ-005 (原装进口) 心钠素 (ANP)
50-1600 (pg/ml) 0.0625-2 (ng/ml)
肾性高血压，原发性醛固酮增多症
25 尾加压素 UII (UII) 皮质醇结合球蛋白 (CBG) 皮质类固醇结合球蛋白(VP)
37℃/45m
200
48/RT 2h/RT +35m
100
7200 糖尿病及 Cushing 综合症，Add-isuan 病及 Sheehan 综合症糖尿病及 Cushing 综合症，Add-isuan 病及 Sheehan 综合症
1000 1500
RP-050
P 物质 (S.P)
5-1215 (pg/ml)
非平衡法 24h+24h
50 100
1000 1500
RP-051
血管活性肠肽 (VIP)
40-5120 (pg/ml)
非平衡法 24h+24h
50 100
1000 1500
RP-052
生长抑素 (SS)
40-5120 (pg/ml)
肌钙蛋白 (C-TnT) 脂肪酸结合蛋白 (FABP) 血管紧张素Ⅰ （肾素活性） (AⅠ/PRA) 肾素活性（Renin）血管紧张素Ⅱ (AⅡ)
RK-016 RJ-016 (原装进口) RK-017
高血压分型，治疗用药指导

ADC药物研发现状

Title Originator Highest Dev Status 111In-capromab pendetide Cytogen Corp Launched111In-imciromab pentetate Janssen Biotech Inc Launched131I-chTNT-1/B Peregrine Pharmaceuticals Inc Launched131I-metuximab Fourth Military Medical University PLA Launchedbrentuximab vedotin Seattle Genetics Inc Launchedgemtuzumab Wyeth Research Launchedibritumomab tiuxetan IDEC Pharmaceuticals Corp Launchedtrastuzumab emtansine Genentech Inc LaunchedATL-101, ATLAB Cornell University Phase 3 Clinical inotuzumab ozogamicin Wyeth Research Phase 3 Clinical oportuzumab monatox (intratumoral, head and neck cancer), Viventia University of Zurich Phase 3 ClinicalRIGS CC49Navidea Biopharmaceuticals Inc Phase 3 ClinicalABT-414Abbott Laboratories Phase 2 ClinicalCDX-1401Celldex Therapeutics Inc (pre-merger)Phase 2 Clinical glembatumumab vedotin CuraGen Corp Phase 2 ClinicalLMB-2National Cancer Institute Phase 2 Clinical lorvotuzumab mertansine ImmunoGen Inc Phase 2 Clinical moxetumomab pasudotox National Cancer Institute Phase 2 Clinical oportuzumab monatox (intravesicular, bladder cancer), Viventia University of Zurich Phase 2 ClinicalPSMA-ADC Cytogen Corp Phase 2 ClinicalRG-7593Genentech Inc Phase 2 ClinicalRG-7596Genentech Inc Phase 2 ClinicalSAR-3419ImmunoGen Inc Phase 2 Clinical212-Pb-TCMC-trastuzumab National Cancer Institute Phase 1 ClinicalActimab-A PDL BioPharma Inc Phase 1 ClinicalAGS-16M8F Agensys Inc Phase 1 Clinicalanti-CD3/anti-CD20 bispecific antibody-armed activated T-cells (non-Hodgkin's lymphoma), Wayne State University/Barbara Ann KarmanosCancer Institute Barbara Ann Karmanos Cancer Institute Phase 1 ClinicalASG-5ME Agensys Inc Phase 1 ClinicalBAY-79-4620MorphoSys AG Phase 1 Clinical citatuzumab bogatox Viventia Biotech Inc Phase 1 Clinical doxorubicin-loaded anti-EGFR immunoliposomes (solid tumors), UniversityHospital Basel University Hospital of Basel Phase 1 ClinicalHuM195/rGel (intravenous infusion, AML/CML/meylodisplastic syndrome),Targa Therapeutics Memorial Sloan-Kettering Cancer Center Phase 1 ClinicalIMGN-529ImmunoGen Inc Phase 1 ClinicalIMGN-853ImmunoGen Inc Phase 1 ClinicalIMMU-132Immunomedics Inc Phase 1 Clinical labetuzumab-SN-38Immunomedics Inc Phase 1 ClinicalNHS-IL-12National Cancer Institute Phase 1 ClinicalRG-7450Genentech Inc Phase 1 ClinicalRG-7458Genentech Inc Phase 1 Clinical RG-7598Genentech Inc Phase 1 Clinical RG-7599Genentech Inc Phase 1 Clinical RG-7600Genentech Inc Phase 1 Clinical RG-7636Genentech Inc Phase 1 Clinical SAR-566658ImmunoGen Inc Phase 1 Clinical T-Guard University Medical Center St Radboud Phase 1 Clinical vorsetuzumab mafodotin Seattle Genetics Inc Phase 1 Clinical 131I-catuximab (colorectal cancer), Pacific Meinuoke Fourth Military Medical University PLA Discovery177Lu-tetraxetan-tetulomab (non-Hodgkin's lymphoma), Nordic Nanovector Nordic Nanovector AS Discovery227Th-epratuzumab (hematological cancer), Algeta Algeta ASA Discovery227Th-rituximab (cancer), Algeta Algeta ASA Discovery227Th-trastuzumab (cancer), Algeta Algeta ASA Discovery4s3-0014s3 Bioscience Inc Discovery4s3-0024s3 Bioscience Inc Discovery64Cu-NOTA-ALT-836Altor BioScience Corp DiscoveryAA-A225Actinium Pharmaceuticals Inc Discovery AbGn-107AbGenomics Corp Discovery Actimab-B Fred Hutchinson Cancer Research Center Discovery Actimab-C Actinium Pharmaceuticals Inc Discovery Actimab-P Actinium Pharmaceuticals Inc Discovery adalimumab + anti-Ang2 Zybody (rheumatoid arthritis/inflammatory boweldisease), Zyngenia Zyngenia Inc DiscoveryAGS-15E ADC Agensys Inc DiscoveryAGT-160ArmaGen Technologies Inc DiscoveryAGT-185ArmaGen Technologies Inc DiscoveryAGT-190ArmaGen Technologies Inc Discovery amanitin-trastuzumab conjugate (cancer), Heidelberg Pharma Heidelberg Pharma Holding Ltd Discoveryanti-CD133-immunotoxin conjugates (photochemical internalization, cancer),PCI Biotech PCI Biotech Holding ASA Discoveryanti-ET8R-MC-vc-PAB-MMAE Genentech Inc Discoveryanti-NaPi3b antibody-drug conjugate (cancer), Genentech/Roche Genentech Inc Discovery antibody drug conjugates (cancer), Sanofi Sanofi Discovery antibody-drug conjugates (cancer), ADC Therapeutics ADC Therapeutics Sarl Discovery antibody-drug conjugates (cancer), Seattle Genetics/Oxford BioTherapeutics Seattle Genetics Inc Discovery antibody-drug conjugates (TAP, cancer), Lilly Eli Lilly & Co Discovery antibody-IFN lambda conjugates (cancer), Immunomedics Immunomedics Inc Discovery anticancer therapy (TAP technology), Amgen Amgen Inc DiscoveryAPH-0912Aphios Corp Discovery Aurixin BioIntegrator DiscoveryAZ-05Allozyne Inc Discovery BIOO-1BIOO Therapeutics DiscoveryBIOO-2BIOO Therapeutics Discovery BIOO-3BIOO Therapeutics Discovery BIOO-4BIOO Therapeutics Discovery BIOO-5BIOO Therapeutics Discovery BIOO-6BIOO Therapeutics Discovery BIOO-7BIOO Therapeutics Discovery botulinum toxin B inhibitor (injectable, heteropolymer mAbs, botulism),Immunome Immunome Inc Discovery BT-2111biOasis Technologies Inc Discovery C2-2b-2b Immunomedics Inc Discovery CDX-014CuraGen Corp Discovery chiHEA-125-Ama Heidelberg Pharma Holding Ltd Discovery CK-22-(20)-(20)Immunomedics Inc Discovery complement factor H-derived short consensus repeat-antibody constructs(infection), LysoVac University of Innsbruck Discovery Cymac-001Cytoguide ApS Discovery CYP-Ab Cytune Pharma Discovery D2C7-based immunotoxins (glioma), Duke University Duke University Discovery EGFR modulators (antibody conjugates, PIT, cancer), Aspyrian Aspyrian Therapeutics Inc Discovery engineered cysteine drug conjugates mAbs (cancer), Seattle Genetics Seattle Genetics Inc Discovery epratuzumab-SN-38Immunomedics Inc Discovery ETBs (cancer), Molecular Templates/ Imclone Molecular Templates Inc Discovery Fluorescent-labeled bevacizumab (imaging, ocular disease), Mivenion mivenion Gmbh Discovery gemcitabine + paclitaxel (prodrug, nanomAb, cancer), ImmunePharmaceuticals Immune Pharmaceuticals Corp Discovery Herceptin:Endostatin-P125A University of Miami Discovery hLL1-CL2A-SN-38Immunomedics Inc Discovery hPAM4-CL2A-SN-38Immunomedics Inc Discovery human monoclonal antibody-toxin conjugates (myocardial infarction), Celdara Celdara Medical LLC Discovery HuMax-TF-ADC Genmab A/S Discovery IFNalpha-fused mAbs (HBV infection), Roche Roche Holding AG Discovery IL-13 receptor alpha 2 inhibitors (iv, cancer), Pfizer Pfizer Inc Discovery IMGN-289ImmunoGen Inc Discovery intracellular antibodies (Intraphilin, inflammatory diseases/infectiousdiseases/ophthalmic diseases), Permeon Biologics Permeon Biologics Inc Discovery mapp-66Mapp Biopharmaceutical Inc Discovery MB-2003Mapp Biopharmaceutical Inc Discovery monoclonal antibody-drug conjugates, Chirogenix/ImmunoGen/Celltrion Chirogenix Co Ltd Discovery MP-Ter-ADC MediaPharma Srl Discovery N01-OX2Intellect Neurosciences Inc Discovery PC-91ProCell Therapeutics Inc Discovery ProstaLite PhotoBiotics Ltd Discoveryrecombinant mAb-biocide fusion proteins (oral/Directed Biocide,cryptosporidium infection), ioGenetics ioGenetics Inc Discovery SGN-CD33A Seattle Genetics Inc Discovery SGN-LIV1A Seattle Genetics Inc Discovery SL-101Stemline Therapeutics Inc Discovery SYD-983Synthon Biopharmaceuticals Discovery T01-OX2Intellect Neurosciences Inc Discovery TBL-0306L Transgene Biotek Ltd Discovery TBL-0306M Transgene Biotek Ltd Discovery TBL-0805E Transgene Biotek Ltd Discovery thio-trastuzumab-mpeo-DM1Genentech Inc Discovery trastuzumab-PNU-159682 antibody-drug conjugate (cancer), Genentech Genentech Inc Discovery veltuzumab-IFN alpha 2b conjugate (cancer), IBC/Immunomedics IBC Pharmaceuticals Inc Discovery BIIB-015Biogen Inc Suspended Pretarget technology (gastrointestinal adenocarcinoma), NeoRx Poniard Pharmaceuticals Inc Suspended125I-AnnA1 IgG Sidney Kimmel Cancer Center No Development Reported131I-CC49-SCA Enzon Labs Inc No Development Reported177Lu-capromab pendetide Cytogen Corp No Development Reported90Y-capromab pendetide Cytogen Corp No Development Reported99mTC-BERH2Medac GmbH No Development Reportedanti-CD133-vcMMAF Seattle Genetics Inc No Development Reportedanti-CD22 antibody drug-conjugates, Medarex/BMS Medarex Inc No Development Reportedanti-PSMA antibody-drug conjugates (cancer), Medarex Medarex Inc No Development Reportedantibody-drug conjugates (solid tumors), Daiichi Sankyo Seattle Genetics Inc No Development ReportedAVE-9633ImmunoGen Inc No Development Reportedbectumomab Immunomedics Inc No Development ReportedCA125/MUC16-targeting antibody-drug conjugate (ovarian cancer),Genentech Genentech Inc No Development Reportedcathepsin B-sensitive prodrugs, BMS Bristol-Myers Squibb Pharmaceutical ResearchInstituteNo DevelopmentReportedCC49 humanized radioimmunoconjugates, National Cancer Institute,University of Alabama at Birmingham National Cancer Institute No Development ReportedCD4-BFFI Roche Holding AG No Development ReportedCHB-111ViRexx Medical Corp No Development ReportedCHT-25University College London No Development ReportedCMD-193Wyeth No Development ReportedCNTO-95 immunoconjugates (cancer), Centocor Janssen Biotech Inc No Development Reportedconjugated PEI/anti-CD133 mAb plasmid-based gene therapy (brain tumor),Discovery genomics Discovery Genomics Inc No Development ReportedcT84.66City of Hope No Development Reporteddelta 9-cadherin targeting antibody (gastric cancer), Actinium Helmholtz Zentrum München No Development Reporteddiphtheria toxin, RCT Research Corporation Technologies No Development Reporteddoxorubicin-C225 conjugate (STEALTH), SEQUUS SEQUUS Pharmaceuticals Inc No Development ReportedDTPA-BrE-3University of Colorado System No Development ReportedDXL-625InNexus Biotechnology Inc No Development ReportedG3.519-PAP-S Tanox Inc No Development ReportedhuHMFG1-caspase Antisoma plc No Development ReportedIMGN-007ImmunoGen Inc No Development ReportedIMGN-009ImmunoGen Inc No Development Reportedimmunoconjugate (cancer MN), Bayer Bayer AG No Development ReportedImmuRAID-AFP-99mTc, Immunomedics Immunomedics Inc No Development ReportedIMTOX 22-97A University of Texas Southwestern MedicalCenterNo DevelopmentReportedKSB-201KS Biomedix Holdings plc No Development ReportedLA22-radioimmunoconjugates (cancer), Welson/Peking University Welson Pharmaceuticals Inc No Development Reportedlabetuzumab Immunomedics Inc No Development ReportedLMB-1, NIH National Institutes of Health No Development ReportedLu-177-trastuzumab Tarbiat Modares University No Development ReportedLymphoScan Immunomedics Inc No Development ReportedMDX-11Medarex Inc No Development ReportedMDX-1203Medarex Inc No Development ReportedMDX-1206Medarex Inc No Development Reportedmonoclonal-porphyrins, Quadra Logic QLT Inc No Development Reportedmonoclonals, Quest Quest Biotechnology Inc No Development ReportedNogo receptor modulators, Biogen Idec Yale University No Development ReportedONS-1210Oncobiologics Inc No Development ReportedOP-06 program (cancer), Onco-Pharmakon Onco-Pharmakon Inc No Development Reportedpaclitaxel analogs and immunoconjugates (cancer), Bioxel Bioxel Pharma Inc No Development ReportedPE38-conjugated anti-CD30 immunotoxin, NCI National Cancer Institute No Development Reportedprostate-specific MAb, NIH National Institutes of Health No Development ReportedR-1549The UK Imperial Cancer Research Fund No Development Reportedradiolabeled Tx3.833Beth Israel Deaconess Medical Center No Development Reportedscu-PA-59D8Bristol-Myers Squibb Co No Development ReportedSGN-17/19Seattle Genetics Inc No Development Reportedtaxane-monoclonal antibody conjugates, ImClone ImClone Systems Inc No Development Reportedtranscobalamin (vitamin B12) receptor-targeting mAbTCR23-saporinconjugate (cancer), Kyto Kyto Biopharma Inc No Development Reportedtrastuzumab-autophilic peptide conjugate (breast cancer), InNexusBiotechnology InNexus Biotechnology Inc No Development Reportedtrastuzumab-MC-vc-PAB-MMAF Genentech Inc No Development ReportedTRP-targeted antibody conjugate (Yttrium 90/MX-DTPA), SomantaPharmaceuticals Immunodex Inc No Development Reportedtucotuzumab celmoleukin EMD Lexigen Research Center Corp No Development ReportedVB4-011Viventia Biotech Inc No Development ReportedVB6-011Viventia Biotech Inc No Development ReportedVB6-050Viventia Biotech Inc No Development ReportedXomaZyme-791XOMA Corp No Development Reportednofetumomab Poniard Pharmaceuticals Inc Withdrawn 131I-81C6Duke University Discontinued 131I-ImmuRAIT-HCG, Immunomedics Immunomedics Inc Discontinued B-B4-DC1ImmunoGen Inc Discontinued CC49 radioimmunoconjugates, University of Alabama at Birmingham University of Alabama at Birmingham Discontinued CD5 monoclonals/RIPs, Italfarmaco Italfarmaco SpA Discontinued CVX-045CovX Pharmaceuticals Inc Discontinued CVX-060CovX Pharmaceuticals Inc Discontinued CVX-241CovX Pharmaceuticals Inc Discontinued CVX-343CovX Pharmaceuticals Inc Discontinued doxorubicin-BR96 conjugate, BMS Bristol-Myers Squibb Co Discontinued doxorubicin-CEA conjugate, Immunomedics Immunomedics Inc Discontinued doxorubicin-LL2 conjugate, Immunomedics Immunomedics Inc Discontinued FAP5-DM1Boehringer Ingelheim Corp Discontinued FGFR4-CovX-Body CovX Pharmaceuticals Inc Discontinued HuM-195-Bi-213PDL BioPharma Inc Discontinued human placental growth factor 1-CVX-2000 monoclonal antibody conjugatedtherapeutic (CovX-body, cancer), CovX CovX Pharmaceuticals Inc Discontinued huN901-CC-1065ImmunoGen Inc Discontinued huN901-DC1ImmunoGen Inc Discontinued ImmuRAID-HCG-99mTc, Immunomedics Immunomedics Inc Discontinued ImmuRAIT-CEA-rhenium-188, Immunomedics Immunomedics Inc Discontinued MDX-214Medarex Inc Discontinued MEDI-547MedImmune LLC Discontinued MLN-2704Cornell University Discontinued Oncolym Peregrine Pharmaceuticals Inc Discontinued Oncolysin B Dana-Farber Cancer Institute Inc DiscontinuedOncolysin CD6Dana-Farber Cancer Institute Inc Discontinued Oncolysin M Dana-Farber Cancer Institute Inc Discontinued Oncolysin S Dana-Farber Cancer Institute Inc Discontinued Oncopurge Poniard Pharmaceuticals Inc Discontinued rhenium-188-LL2, Immunomedics Immunomedics Inc Discontinued SMART ABL-364Novartis AG Discontinued targeted ranpirnase conjugates (cancer), Alfacell Tamir Biotechnology Inc DiscontinuedHighest Dev Status。

Quinine HCl Dihydrate_钾通道抑制剂_6119-47-7_Apexbio

产品说明书
化学性质
产品名: Cas No.: 分子量: 分子式: 化学名:
SMILES: 溶解性: 储存条件: 一般建议:
运输条件:
生物活性
靶点 : 信号通路: 产品描述: Quinine HCl Dihydrate 参考文献:
产品名: Quinine HCl Dihydrate 修订日期: 6/30/2016
Quinine HCl Dihydrate 6119-47-7 396.91 C20H24N2O2.HCl.2H2O (R)-[(2S,4S,5R)-5-ethenyl-1-azabicyclo[2.2.2]octan-2-yl]-(6-methoxyq uinolin-4-yl)methanol;dihydrate;hydrochloride COC1=CC2=C(C=CN=C2C=C1)C(C3CC4CCN3CC4C=C)O.O.O.Cl >19.45mg/mL in DMSO Store at -20°C For obtaining a higher solubility , please warm the tube at 37°C and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20°C for several months. Evaluation sample solution : ship with blue ice All other available size: ship with RT , or blue ice upon request
ApexBio Technology
特别声明
产品仅用于研究，不针对患者销售，望谅解。每个产品具体的储存和使用信息显示在产品说明书中。ApexBio 产品在推荐的条件下是稳定的。产品会根据不同的推荐温度进行运输。许多产品短期运输是稳定的，运输温度不同于长期储存的温度。我们确保我们的产品是在保持试剂质量的条件下运输的。收到产品后，按照产品说明书上的要求进行储存。

E 64d_半胱氨酸蛋白酶抑制剂_88321-09-9_Apexbio

sales@ E 64d半胱氨酸蛋白酶抑制剂Evaluation Sample客户使用Apexbio产品发表的文献质量控制质量控制和MSDSCOA (Certificate Of Analysis)HPLCMS (Mass Spectrometry)NMR (Nuclear Magnetic Resonance)MSDS (Material Safety Data Sheet)化学性质CAS号88321-09-9SDF Download SDF 化学名ethyl (2S,3S)-3-[[(2S)-4-methyl-1-(3-methylbutylamino)-1-oxopentan-2-yl]carbamoyl]oxirane-2-carboxylate SMILES CCOC(=O)C1C(O1)C(=O)NC(CC(C)C)C(=O)NCCC(C)C分子式C17H30N2O5分子量342.43溶解性Soluble in DMSO > 10 mM储存条件Store at -20°C一般建议为了使其更好的溶解，请用37℃加热试管并在超声波水浴中震动片刻。

储液可以在零下20℃中保存数月。

运输条件试用装：蓝冰运输。

其他可选规格：常温运输或根据您的要求用蓝冰运输。

生物活性E-64d (合成的E-64的类似物、E-64c的乙基酯)是一个不可逆的、膜通透性的溶酶体和胞浆半胱氨酸蛋白酶抑制剂，抑制钙蛋白酶（calpain）和半胱氨酸蛋白酶cathepsins F、K、B 、H和L。

.靶点cathepsins F cathepsins K cathepsins B cathepsins H cathepsins LIC50实验报告细胞实验[1]：细胞系血小板溶解方法在DMSO中的溶解度>10 mM。

为了获得更高的浓度，可以将离心管在37℃加热10分钟和/或在超声波浴中震荡一段时间。

原液可以在-20℃以下储存几个月。

ESI-09_EPAC抑制剂_263707-16-0_Apexbio

参考文献: [1]. Almahariq M, Tsalkova T, Mei FC, et al. A novel EPAC-specific inhibitor suppresses pancreatic cancer cell migration and invasion. Mol Pharmacol, 2013, 83(1): 122-128. [2]. Zhu Y, Chen H, Boulton S, et al. Biochemical and pharmacological characterizations of ESI-09 based EPAC inhibitors: defining the ESI-09 ""therapeutic window"". Sci Rep, 2015, 5: 9344.
Evaluation sample solution : ship with blue ice All other available size: ship with RT , or blue ice upon request
生物活性
靶点 :
Others
信号通路:
Others
产品描述:
ESI-09 是 EPAC 的特异性抑制剂,对 EPAC2 和 EPAC1 的 IC50 值分别为 1.4 和 3.2 M[1]. cAMP/cAMP 调控的鸟苷酸交换因子(EPAC/cAMP-GEF)是一种响应于胞内 cAMP 的小 GTPases Rap1 和 Rap2 的鸟苷酸交换因子[2]. ESI-09 是一种 EPAC 的特异性抑制剂.ESI-09(25 M)在 25 M 的 cAMP 存在时可将 EPAC1 和 EPAC2 GEF 活性降低到基础水平.在 25 M 的 cAMP 存在时,ESI-09 可抑制 cAMP 介导的 EPAC2 和 EPAC1

毒西药---黑名单

毒西药---黑名单*导读：知道毒西药---黑名单，以减少伤害。

……1,Chloroquine(磷酸氯化喹啉，Chloroquine Phosphate)有些患者不知不觉地出现精神病症状，如激动不安、寻衅、精神错乱、人格改变或抑郁，有时抑郁很严重。

国内曾报告3例发生精神病，其中1例最后跳楼自杀。

2,右旋糖酐:有发生过敏反应的危险，其症状很不一定，有潮红、荨麻疹、瘙痒、结膜炎、血管神经性水肿、胸部压迫感、血压下降、喘鸣、呼吸困难、恶心、呕吐，重者口唇发绀，个别出现循环衰竭，甚至出现过敏性休克。

致死性反应主要发生于老年人。

3,Polygeline(尿素交联明胶，Haemaccel)最近报告有些病例发生过敏反应，也有荨麻疹、血管神经性水肿、潮红、发热、呼吸困难及休克。

4,Hetastarch(Hydroxyethyl Starch)报告有过敏反应，静脉输入时可产生恶心、呕吐、轻度发热、头痛、皮疹、瘙痒，有时影响肝肾功能，可能干扰凝血机制，延长出血时间。

5,Polyvidone(聚乙烯吡咯烷酮，PVP，Povidonl)有报道不良反应：咳痰、血痰、黄疸、蛋白尿、急性肾功能不全、血尿、吐血、乏力、倦怠、食欲不振、上眼睑浮肿、发热等。

此外，还有肝大、低胆固醇血症、凝血功能障碍等。

6,链霉素、磺胺等可引起人体的变态反应，如处理不当，会危及患者的生命。

7,Pyrimethamine(息疟定。

Daraprim)此药可致白细胞减少、粒细胞减少、血小板减少、全细胞减少及巨幼红细胞贫血。

吕氏等报告100例服用乙胺嘧啶食盐预防疟疾，引起巨幼红细胞贫血，最早发生在服药后25天，最晚在134天，1例死亡。

8,Cyclophosphamide(环磷氮芥，癌得星，Endoxan，Cytoxan) 常见的不良反应为胃肠不能耐受、骨髓受抑制、脱发及无菌性膀胱炎，有报告，护士处理此药时可发生过敏反应。

此药也可引起出血性膀胱炎及膀胱纤维化，这是立即或永久停药的指征，否则将发生膀胱癌。

Ximelagatran_凝血酶抑制剂_192939-46-1_Apexbio

特别声明
产品仅用于研究，
不针对患者销售，望谅解。
每个产品具体的储存和使用信息显示在产品说明书中。ApexBio 产品在推荐的条件下是稳定的。产品会根据不同的推荐温度进行运输。许多产品短期运输是稳定的，运输温度不同于长期储存的温度。我们确保我们的产品是在保持试剂质量的条件下运输的。收到产品后，按照产品说明书上的要求进行储存。
参考文献: [1]. Carlsson S, Elg M, Mattsson C. Effects of ximelagatran, the oral form of melagatran, in the treatment of caval vein thrombosis in conscious rats. Thromb Res, 2002, 107(3-4): 163-168. [2]. Sarich TC, Eriksson UG, Mattsson C, et al. Inhibition of thrombin generation by the oral direct thrombin inhibitor ximelagatran in shed blood from healthy male subjects. Thromb Haemost, 2002, 87(2): 300-305. [3]. Whlander K, Lapidus L, Olsson CG, et al. Pharmacokinetics, pharmacodynamics and clinical effects of the oral direct thrombin inhibitor ximelagatran in acute treatment of patients with pulmonary embolism and deep vein thrombosis. Thromb Res, 2002, 107(3-4): 93-99.

Furagin_抗菌,呋喃妥因类似物_1672-88-4_Apexbio

Evaluation sample solution : ship with blue ice All other available size: ship with RT , or blue ice upon request
生物活性
靶点 :
Microbiology & Virology
信号通路:
Antibiotic
产品描述:
Furagin is an anti-bacterial, nitrofurantoin analog with the same efficacy in treating acute cystitis as Ciprofloxacin; however, the duration of therapy is longer.
1-[(E)-[(E)-3-(5-nitrofuran-2-yl)prop-2-enylidene]amino]imidazolidin e-2,4-dione
C1C(=O)NC(=O)N1N=CC=CC2=CC=C(O2)[N+](=O)[O-]
Soluble in DMSO
Store at -20°C
For obtaining a higher solubility , please warm the tube at 37°C and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20°C for several months.
ApexBio Technology
参考文献:特别ຫໍສະໝຸດ 明产品仅用于研究，不针对患者销售，望谅解。每个产品具体的储存和使用信息显示在产品说明书中。ApexBio 产品在推荐的条件下是稳定的。产品会根据不同的推荐温度进行运输。许多产品短期运输是稳定的，运输温度不同于长期储存的温度。我们确保我们的产品是在保持试剂质量的条件下运输的。收到产品后，按照产品说明书上的要求进行储存。

S18886_强效血栓素A2(TP)抑制剂_165538-40-9_Apexbio

产品描述:
IC50: 16.4 nM for TP receptor S18886 is a potent thromboxane A2 (TP) inhibitor. The lipid mediator thromboxane A2 (TXA2) plays a critical role in platelet aggregation and vascular and bronchial smooth muscle constriction. The actions of TXA2 are mediated via the
ApexBio Technology
(6R)-6-[[(4-chlorophenyl)sulfonyl]amino]-5,6,7,8-tetrahydro-2-meth yl-1-naphthalenepropanoic
CC1=C(CCC(O)=O)C2=C(C=C1)C[C@H](NS(C3=CC=C(Cl)C=C3)(=O)=O) CC2
Soluble in DMSO
Store at -20°C
For obtaining a higher solubility , please warm the tube at 37°C and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20°C for several months.
产品说明书
化学性质
产品名: S18886 修订日期: 6/30/2016
产品名: Cas No.: 分子量: 分子式: 别名: 化学名:
SMILES:
溶解性: 储存条件: 一般建议: